←
Not So Profound (beta)2,812 posts
Not So Profound (beta) avatar

Not So Profound (beta)

@NotSoProf0und

Deep insight and dank memes for misfits at the raw edge of consciousness & spirituality ➠ straight to your inbox.

◷ Joined November 2022▧ 778 Photos and videos
Not So Profound (beta) avatar
Not So Profound (beta)@NotSoProf0und·Mar 5

In 1989, a small tech company sued a government-backed consortium for allegedly stealing their research. Standard Silicon Valley IP dispute. One problem: the founders were also running an illegal MDMA lab in Mexico producing 20kg a month. This is a true story 🧵

Post attachment
Tomas avatar
⟳ Not So Profound (beta) retweeted
Tomas@evolvee33·Nov 17

Albert Hofmann discovered the most powerful hallucinogen known to science, took it himself, and became convinced he was dying. What happened next would change the way humanity understood the mind. He was 37, a Swiss chemist working for Sandoz laboratories in Basel. In 1938 he had synthesized the twenty-fifth compound in a series derived from a fungus that grows on rye. It showed little promise. His colleagues lost interest. The substance was shelved. Five years later, something made him return to it. On April 16, 1943, while working in his laboratory, Hofmann began feeling strangely intoxicated. He went home, lay down, and closed his eyes. Extraordinary shapes appeared. Colors moved in patterns he had never seen. For two hours, his imagination seemed to have escaped the limits of his own mind. He suspected the chemical. Three days later he swallowed a measured dose of LSD-25. He believed he was being cautious. Within an hour he could barely write. His assistant helped him onto a bicycle. As they rode through Basel, the streets bent and twisted. Buildings seemed to move. He felt as though he were standing still, although they were cycling at considerable speed. At home he became convinced he was dying. His neighbor appeared to him as a terrifying witch. The furniture took on monstrous forms. A doctor examined him and found no serious physical abnormality beyond dilated pupils. Then the terror passed. The same substance that had convinced him he was losing his mind now filled his vision with extraordinary beauty. He watched colors explode behind closed eyes. Every sound seemed to transform into an image. By the following morning he felt renewed, and the world appeared unusually alive. Sandoz began distributing LSD to psychiatrists in 1947. Researchers investigated it for alcoholism, depression, and other conditions. Some believed it could reveal the workings of psychosis. Others believed it could help patients see beyond the psychological defenses that years of therapy had failed to penetrate. Then LSD escaped the laboratory. By the 1960s it had become a symbol of rebellion, spiritual awakening, and the collapse of conventional authority. Governments moved to prohibit it. Research largely stopped. A substance once distributed to psychiatrists became one of the most feared drugs in the Western world. Hofmann watched the transformation with dismay. He had hoped his discovery would be used carefully to investigate consciousness. Instead, the world had turned what he considered a potentially valuable medicine into a cultural battlefield. He lived to be 102. The man who had briefly believed a chemical was going to kill him spent the rest of his life arguing that it might help humanity understand what it means to be alive. And the substance that governments spent decades trying to keep out of human minds is now being studied again for what it might reveal about them.

Post attachmentPost attachment
Balázs Szigeti avatar
⟳ Not So Profound (beta) retweeted
Balázs Szigeti@psybalazs·Nov 17

Congratulations to @Helus_Pharma pharma for great #trial results! There is a normal placebo response of ~10 MADRS units even after the first dose (which is about the same as in most depression trials) and increases to ~15 after the second dose. Even better is that the between-arm difference is a very good ~5-7 MADRS units against this normal #placebo response. Given the headache of extremely low placebo responses in other psychedelic trials, there are two big picture questions that go beyond #psychedelics: - Should not the magnitude of the placebo response be a part of how we evaluate treatments?! Most regulatory agencies / scientist focus almost exclusively on the between-arm difference, but a between-arm difference of (lets say) 4 MADRS units is very different against a placebo response of 3 or 10 MADRS units - they translate to a patient improvement after the treatment of ~7 and ~14 MADRS units, respectively. You would not notice patients are doing twice as well in the second case without knowing what happened in the placebo arm! - Why was the placebo response here ~2x as large as in other psychedelic for major depression trials? I strongly suspect it is a combination of contextual factors (e.g. how the study was advertised), but we will never know as these factors are rarely documented. Half of medical research is placebo, yet we spend virtually nothing to understand what drives the giant variability in placebo responses.

Soumya avatar
⟳ Not So Profound (beta) retweeted
Soumya@ecstatic_0·Nov 18

Happiness is felt in the Now. You can't experience happiness in the past or future, in time. Happiness is now or never. The bliss of God is experienced now or never.

Dr. Rick Barnett, PsyD 😊 avatar
⟳ Not So Profound (beta) retweeted
Dr. Rick Barnett, PsyD 😊@drrickbarnett·Nov 16

Just a heads up on the cost of medicalized psilocybin treatment with @FDA approval. About $20k per dosing session. Up to $60k for three dosing sessions. Prep and integration billed separately. Talk about hard to swallow.

Post attachmentPost attachment
Martijn Arns avatar
⟳ Not So Profound (beta) retweeted
Martijn Arns@Brainclinics·Nov 16

Three different psychedelics, three different indications, one disorder... How to read psychedelic trial outcomes in depression Psychedelics produce an unmistakable experience, so most patients know what they got. True double-blinding is impossible, and that undermines Δ-MADRS and effect sizes, because both depend on the placebo arm. A more robust read: compare active-arm remission with large open-label effectiveness data. Both then include specific + non-specific effects, a fair proxy for what you’d see in clinical practice. Second, indication matters. MDD, adjunctive and TRD carry very different expected remission rates. STAR*D (~4,000 pts, sequential treatment steps) shows remission falling 37% → 31% → 14% → 13% with each failed treatment (inset). Read in that context: • $CMPS COMP360: 18% blinded looks low, but beats STAR*D step 3 (14%) in TRD; 30% open-label is on par with TMS (29.5%) • $DFTX DT120: 24% in MDD sits below STAR*D steps 1–2, though higher 46% remisison with redosing/follow-up (interim data) • $HELP HLP003: highest remission (51%) and highest placebo (18%), likely reflecting add-on to ongoing AD + EMBARK psychological support Cross-trial; definitions differ.

Post attachment
60 Minutes avatar
⟳ Not So Profound (beta) retweeted
60 Minutes@60Minutes·Nov 14

Kratom can be as easy to obtain as a bag of chips, and it's become a billion-dollar industry. Increasingly, though there’s outrage that kratom, an opioid that can lead to addiction and death, remains legal in most states. 60 Minutes reports, Sunday.

0:22
Andrew D. Huberman, Ph.D. avatar
⟳ Not So Profound (beta) retweeted
Andrew D. Huberman, Ph.D.@hubermanlab·Nov 16

The new Huberman Lab episode is out: Mushrooms for the Mind & Immune System | @PaulStamets 0:00 Paul Stamets 3:25 Fungal Evolution, Complexity; Natural Intelligence 10:02 Fungi Geography, Mycelium & Immune System 15:10 Sponsors: Eight Sleep & Our Place 17:43 Journey into Mycology, Brother 21:14 Primates & Eating Fungi, Poison; Nutrition, Fetal Health 25:14 Medicinal Mushrooms, Antiviral Properties 30:26 COVID Pandemic, Turkey Tail, Agarikon, Vaccine Enhancement 39:42 Sponsor: AG1 40:33 Enhance Immune System, Vaccines & Medicine, Agarikon, Entourage Effect 47:47 Pharmaceuticals & Natural World 53:28 Mushroom Supplements for Colds, Turkey Tail, Agarikon; Research 1:01:28 Skeptics; Future Pandemics, H5N1, Biodiversity Importance, Natural Products 1:10:28 Sponsor: Joovv 1:11:39 Psilocybin, Depression, Heroic Dose 1:16:51 Psilocybin, Legality, People with Increased Risk, Benefits 1:21:41 Psychedelic Therapies, Neuroplasticity, Therapeutic Support 1:27:36 Psychedelics & Legalization; Psilocybin 1:34:35 Sponsor: Function 1:36:12 Kids, Psilocybin; Microdose, Pharmaceutical Version vs Mushroom 1:42:11 Microdose, Doses; Sensory Perception 1:48:14 Microdosing, Stamets Stack, Mood, Anxiety, Psychomotor Benefits 1:54:10 Cognitive Mushroom Supplements, Cordyceps, Lion’s Mane, Reishi 1:59:55 Mycelium Networks, Electrical Communication; Asteroid, Tryptamine 2:09:48 Fungi on Skin & Gut, Antifungals 2:13:28 Mycoremediation, Fungi & Environmental Pollutants 2:19:27 Tool: Push-Ups; Longevity, Creativity, Happiness 2:27:01 Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Social Media, Neural Network Newsletter Includes paid partnerships.

2:28:56
Harry Pack 👁🌵👁 avatar
⟳ Not So Profound (beta) retweeted
Harry Pack 👁🌵👁@harrypackart1·Nov 16

A mind bending glimpse from the other side, lifting the curtain & opening wide, the dreams that you had which were lost in this realm, as the elves turn the cogs & you see through the veil 🌳🛸 Next part of the upcoming loop pack from @KeVisuals1 & myself. As always any shares much appreciated… 🎶 Doohicky - Supersillyus #ufodisclosure

0:10
Dr Anne Katrin Schlag avatar
⟳ Not So Profound (beta) retweeted
Dr Anne Katrin Schlag@Dr_Anne_Schlag·Nov 15

Beautifully written blog about the recent World Ayahuasca Forum @ProfDavidNutt drugscience.org.uk/the-uncer…

青巌 宗晃( Seigan Soukou ) avatar
⟳ Not So Profound (beta) retweeted
青巌 宗晃( Seigan Soukou )@atahuta123·Nov 14

お坊さんなのでハッキリ言いますが、我慢強いことを美徳にする風潮はあまりよくないと思います。ブッダですら悟るための苦行を6年したあげくに、「もうええわ」と諦めてお粥を食べました。そしたらその日に悟りを開いたんです。我慢し過ぎは無駄です。

60 Minutes avatar
⟳ Not So Profound (beta) retweeted
60 Minutes@60Minutes·Aug 16

Nearly a year after attending a psychedelics retreat, eight of the nine veterans told 60 Minutes their symptoms improved and called their experience “life-changing.” One veteran said the treatment worsened his condition. cbsn.ws/4i6QXMh

1:29
Not So Profound (beta) avatar
Not So Profound (beta)@NotSoProf0und·Nov 14

Overall, good intentions, however... You can’t “open-source” a medicine rooted in Indigenous knowledge, cut out the people who protected it for generations, and call it progress either. That’s just colonial biopiracy with better PR. Let’s not forget where ibogaine comes from 🇬🇦 Iboga is a sacred medicine with deep roots in Gabon’s Bwété traditions, long before Western researchers, pharmaceutical companies, or American politicians took an interest. Plus, Gabon passed a decree in May 2026 specifically protecting iboga, its derivatives, and associated traditional knowledge, including requirements for community consultation and benefit-sharing. So @mcuban and @RobertKennedyJr, I have some serious questions: Are Gabonese elders, traditional knowledge holders, and local communities actually being invited to the table? Are they going to have a say in how this medicine is researched, developed, and commercialized? I’m all for affordable ibogaine and the potential to help millions of people... but making a medicine accessible doesn’t automatically make the process ethical. If American companies get the funding, recognition, and profits while Gabonese communities get nothing, we’re just repeating the same old colonial playbook. You can't claim to be pioneering a new era of healing while ignoring the people and cultures that made it possible. The psychedelic renaissance shouldn't become another chapter of colonial extraction.

Secretary Kennedy brought in @mcuban's Cost Plus Drugs to produce ibogaine here at home, with transparent contracts and prices on par with generics. “We’re going to open source every aspect of this system.”

0:45
Not So Profound (beta) avatar
Not So Profound (beta)@NotSoProf0und·Nov 13

Still bullish on $CMPS despite the turbulence. Best case is @FDA approval by December 2026. Worst case is approval by January 2027.

“Dead all summer” is difficult to square with Lipfendra and Rasonque (both drugs with CNPVs) completing their NDA submissions after Makary’s departure and receiving approval 23 and 40 days later respectively. Relevant precedent for $CMPS, which also uses a rolling NDA submission. Portions of its application have already been under review for months. No guarantee of identical timing, but existing vouchers seemingly still carry meaningful weight.